LPL Financial
REGN icon

LPL Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

LPL Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,700
Closed -$1.21M – 5484
2024
Q4 		$1.21M Buy
+1,700
New +$1.43M ﹤0.01% 3334

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

LPL Financial's REGN Position: Q1 2026 in Review

LPL Financial increased its Regeneron Pharmaceuticals (REGN) stake by 2.2% in Q1 2026, buying an estimated $1.05M and bringing the position to 63,987 shares worth $49.4M. The position accounts for 0.01% of the portfolio, ranked #926.

LPL Financial first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $52.2M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • LPL Financial held 63,987 shares of Regeneron Pharmaceuticals worth $49.4M as of Q1 2026.
  • LPL Financial bought 1,368 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.05M.
  • Regeneron Pharmaceuticals made up 0.01% of LPL Financial's portfolio in Q1 2026, its #926 holding.
  • LPL Financial first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • LPL Financial's Regeneron Pharmaceuticals position peaked at $52.2M in Q3 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.